ThromboGenics NV (TBGNF) Business Update
5/16/2013 10:29:35 AM
More...
|
ThromboGenics Ltd. (THR.BR)' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, Now Launched in the UK
4/11/2013 10:18:26 AM
More...
|
ThromboGenics NV (TBGNF)'s JETREA® Granted EU Approval for Vitreomacular Traction (VMT), Including When Associated With Macular Hole of Diameter Less Than or Equal to 400 Microns
3/15/2013 10:05:00 AM
More...
|
ThromboGenics NV (TBGNF) Announces Business Update and 2012 Full-Year Results
3/15/2013 9:45:00 AM
More...
|
ThromboGenics NV (TBGNF), Novartis AG (NVS) Win EU OK for Jetrea Eye Drug
1/18/2013 7:28:48 AM
More...
|
FDA: ThromboGenics NV (TBGNF) Main Drug Cleared for U.S. Launch
10/18/2012 7:26:49 AM
More...
|
ThromboGenics NV (TBGNF) - Business Update
8/30/2012 10:34:20 AM
More...
|
ThromboGenics NV (TBGNF) Announces Publication of The New England Journal of Medicine Paper Entitled "Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes"
8/20/2012 10:38:24 AM
More...
|
FDA Advisory Committee Recommends ThromboGenics NV (TBGNF)' Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
7/30/2012 10:19:43 AM
More...
|
FDA Sees Side Effects With ThromboGenics NV (TBGNF)'s Eye Drug
7/25/2012 7:13:37 AM
More...
|
|